Reston Wealth Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,652 shares of the company’s stock after acquiring an additional 70 shares during the period. Reston Wealth Management LLC’s holdings in Johnson & Johnson were worth $256,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the stock. Moneta Group Investment Advisors LLC grew its position in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the period. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock worth $8,456,643,000 after buying an additional 294,671 shares during the period. Morgan Stanley grew its position in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after buying an additional 3,849,148 shares during the period. Finally, Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $4,609,399,000. 67.57% of the stock is owned by institutional investors.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $172.92 on Wednesday. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $165.50 and its 200-day simple moving average is $161.20. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The firm has a market cap of $449.41 billion, a PE ratio of 35.00, a P/E/G ratio of 2.92 and a beta of 0.54.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.75%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several equities research analysts have recently commented on the stock. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Morgan Stanley restated an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a report on Friday, July 21st. Raymond James boosted their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a report on Monday, July 24th. Barclays boosted their price objective on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a report on Monday, July 24th. Finally, Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $171.80.
Read Our Latest Stock Report on JNJ
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Do S&P 500 Stocks Tell Investors About the Market?
- On Holding Slips Into A More Comfortable Price PointÂ
- Video Game Stocks: How to Invest in Gaming
- 3 Growing Cannabis Stocks Ready To Bloom
- What is Forex and How Does it Work?
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
